Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
329 | 18133 | 41.2 | 77% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | TAMOXIFEN | authKW | 1173263 | 10% | 40% | 1732 |
2 | ESTROGEN RECEPTOR | authKW | 549149 | 8% | 22% | 1479 |
3 | AROMATASE INHIBITORS | authKW | 534774 | 3% | 58% | 553 |
4 | ANASTROZOLE | authKW | 265127 | 1% | 62% | 254 |
5 | AROMATASE INHIBITOR | authKW | 252078 | 2% | 45% | 331 |
6 | EXEMESTANE | authKW | 241247 | 1% | 74% | 195 |
7 | ENDOCRINE THERAPY | authKW | 225441 | 2% | 44% | 305 |
8 | BREAST CANCER | authKW | 214149 | 15% | 5% | 2669 |
9 | FULVESTRANT | authKW | 211882 | 1% | 72% | 175 |
10 | ESTROGEN RECEPTOR BETA | authKW | 173277 | 1% | 40% | 257 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 103595 | 40% | 1% | 7176 |
2 | Endocrinology & Metabolism | 32571 | 17% | 1% | 3116 |
3 | Obstetrics & Gynecology | 6538 | 6% | 0% | 1177 |
4 | Biochemistry & Molecular Biology | 4237 | 17% | 0% | 3058 |
5 | Cell Biology | 2860 | 8% | 0% | 1529 |
6 | Chemistry, Medicinal | 2064 | 4% | 0% | 712 |
7 | Pathology | 1409 | 3% | 0% | 580 |
8 | Pharmacology & Pharmacy | 1281 | 8% | 0% | 1380 |
9 | Reproductive Biology | 436 | 1% | 0% | 240 |
10 | Medical Laboratory Technology | 383 | 1% | 0% | 186 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | STEROID HORMONES SECT | 70066 | 0% | 83% | 50 |
2 | JC HEUSON CANCEROL MAMMAIRE | 33620 | 0% | 67% | 30 |
3 | RECEPTOR BIOL SECT | 23306 | 0% | 33% | 42 |
4 | BREAST | 22375 | 1% | 11% | 125 |
5 | NUCL RECEPTORS CELL SIGNALING | 21097 | 0% | 22% | 56 |
6 | TUMOR ENDOCRINOL | 20646 | 0% | 47% | 26 |
7 | TENOVUS CANC | 16588 | 0% | 27% | 36 |
8 | BREAST ONCOL PROGRAM | 15565 | 0% | 31% | 30 |
9 | MIDLIFE HLTH | 15126 | 0% | 60% | 15 |
10 | LESTER SUE SMITH BREAST | 14829 | 0% | 18% | 50 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | BREAST CANCER RESEARCH AND TREATMENT | 105803 | 4% | 9% | 677 |
2 | JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 93615 | 4% | 8% | 711 |
3 | MOLECULAR ENDOCRINOLOGY | 45195 | 2% | 7% | 391 |
4 | ENDOCRINE-RELATED CANCER | 22047 | 1% | 9% | 148 |
5 | BREAST | 21015 | 1% | 7% | 175 |
6 | STEROIDS | 14575 | 1% | 5% | 196 |
7 | BREAST CANCER RESEARCH | 13681 | 1% | 6% | 134 |
8 | CLINICAL BREAST CANCER | 12200 | 0% | 10% | 75 |
9 | EUROPEAN JOURNAL OF CANCER | 11597 | 1% | 3% | 267 |
10 | EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 11414 | 1% | 6% | 114 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | TAMOXIFEN | 1173263 | 10% | 40% | 1732 | Search TAMOXIFEN | Search TAMOXIFEN |
2 | ESTROGEN RECEPTOR | 549149 | 8% | 22% | 1479 | Search ESTROGEN+RECEPTOR | Search ESTROGEN+RECEPTOR |
3 | AROMATASE INHIBITORS | 534774 | 3% | 58% | 553 | Search AROMATASE+INHIBITORS | Search AROMATASE+INHIBITORS |
4 | ANASTROZOLE | 265127 | 1% | 62% | 254 | Search ANASTROZOLE | Search ANASTROZOLE |
5 | AROMATASE INHIBITOR | 252078 | 2% | 45% | 331 | Search AROMATASE+INHIBITOR | Search AROMATASE+INHIBITOR |
6 | EXEMESTANE | 241247 | 1% | 74% | 195 | Search EXEMESTANE | Search EXEMESTANE |
7 | ENDOCRINE THERAPY | 225441 | 2% | 44% | 305 | Search ENDOCRINE+THERAPY | Search ENDOCRINE+THERAPY |
8 | BREAST CANCER | 214149 | 15% | 5% | 2669 | Search BREAST+CANCER | Search BREAST+CANCER |
9 | FULVESTRANT | 211882 | 1% | 72% | 175 | Search FULVESTRANT | Search FULVESTRANT |
10 | ESTROGEN RECEPTOR BETA | 173277 | 1% | 40% | 257 | Search ESTROGEN+RECEPTOR+BETA | Search ESTROGEN+RECEPTOR+BETA |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | MACGREGOR, JI , JORDAN, VC , (1998) BASIC GUIDE TO THE MECHANISMS OF ANTIESTROGEN ACTION.PHARMACOLOGICAL REVIEWS. VOL. 50. ISSUE 2. P. 151 -196 | 358 | 81% | 497 |
2 | JORDAN, VC , (2003) ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS AS MULTIFUNCTIONAL MEDICINES. 2. CLINICAL CONSIDERATIONS AND NEW AGENTS.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 46. ISSUE 7. P. 1081 -1111 | 302 | 81% | 255 |
3 | HERYNK, MH , FUQUA, SAW , (2004) ESTROGEN RECEPTOR MUTATIONS IN HUMAN DISEASE.ENDOCRINE REVIEWS. VOL. 25. ISSUE 6. P. 869-898 | 293 | 76% | 204 |
4 | PROSSNITZ, ER , ARTERBURN, JB , (2015) INTERNATIONAL UNION OF BASIC AND CLINICAL PHARMACOLOGY. XCVII. G PROTEIN-COUPLED ESTROGEN RECEPTOR AND ITS PHARMACOLOGIC MODULATORS.PHARMACOLOGICAL REVIEWS. VOL. 67. ISSUE 3. P. 505 -540 | 241 | 60% | 23 |
5 | LE ROMANCER, M , POULARD, C , COHEN, P , SENTIS, S , RENOIR, JM , CORBO, L , (2011) CRACKING THE ESTROGEN RECEPTOR'S POSTTRANSLATIONAL CODE IN BREAST TUMORS.ENDOCRINE REVIEWS. VOL. 32. ISSUE 5. P. 597 -622 | 207 | 79% | 76 |
6 | ARIAZI, EA , ARIAZI, JL , CORDERA, F , JORDAN, VC , (2006) ESTROGEN RECEPTORS AS THERAPEUTIC TARGETS IN BREAST CANCER.CURRENT TOPICS IN MEDICINAL CHEMISTRY. VOL. 6. ISSUE 3. P. 181 -202 | 187 | 90% | 106 |
7 | JORDAN, VC , (2003) ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS AS MULTIFUNCTIONAL MEDICINES. 1. RECEPTOR INTERACTIONS.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 46. ISSUE 6. P. 883-908 | 208 | 76% | 251 |
8 | MUSA, MA , KHAN, MOF , COOPERWOOD, JS , (2007) MEDICINAL CHEMISTRY AND EMERGING STRATEGIES APPLIED TO THE DEVELOPMENT OF SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS).CURRENT MEDICINAL CHEMISTRY. VOL. 14. ISSUE 11. P. 1249-1261 | 189 | 86% | 34 |
9 | FAN, P , MAXIMOV, PY , CURPAN, RF , ABDERRAHMAN, B , JORDAN, VC , (2015) THE MOLECULAR, CELLULAR AND CLINICAL CONSEQUENCES OF TARGETING THE ESTROGEN RECEPTOR FOLLOWING ESTROGEN DEPRIVATION THERAPY.MOLECULAR AND CELLULAR ENDOCRINOLOGY. VOL. 418. ISSUE . P. 245 -263 | 153 | 83% | 4 |
10 | MARTINKOVICH, S , SHAH, D , PLANEY, SL , ARNOTT, JA , (2014) SELECTIVE ESTROGEN RECEPTOR MODULATORS: TISSUE SPECIFICITY AND CLINICAL UTILITY.CLINICAL INTERVENTIONS IN AGING. VOL. 9. ISSUE . P. 1437 -1452 | 143 | 79% | 23 |
Classes with closest relation at Level 2 |